Equivalence of salmeterol (S)/fluticasone propionate (FP) combination with S and FP from separate inhalers as determined by sGaw in Japanese and Caucasian asthmatics
M. Kawai, Y. Takemoto, K. Hashimoto, N. Aoyagi, Y. Nishioka, S. L. Stone, A. Gibson, R. D. Kempsford, J. Lotvall (Kyoto, Tokyo, Japan; Greenford, United Kingdom; Goteborg, Sweden)
Source: Annual Congress 2004 - Current treatments for allergic rhinitis and asthma
Session: Current treatments for allergic rhinitis and asthma
Session type: Thematic Poster Session
Number: 850
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Kawai, Y. Takemoto, K. Hashimoto, N. Aoyagi, Y. Nishioka, S. L. Stone, A. Gibson, R. D. Kempsford, J. Lotvall (Kyoto, Tokyo, Japan; Greenford, United Kingdom; Goteborg, Sweden). Equivalence of salmeterol (S)/fluticasone propionate (FP) combination with S and FP from separate inhalers as determined by sGaw in Japanese and Caucasian asthmatics. Eur Respir J 2004; 24: Suppl. 48, 850
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001
Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Non inferiority comparison of salmeterol HFA (SM-HFA) pMDI with salmeterol CFC (SM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007
Onset of action of salmeterol/fluticasone (SFC) in single inhaler vs. salmeterol (S) in patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003
Initiation of treatment with the salmeterol/fluticasone propionate (FP) combination product is better than inhaled steroid alone (FP) in asthmatic patients symptomatic on short-acting bronchodilator alone Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003
The safety of double dose salmeterol/fluticasone proprionate (SFC) in adult asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004
In vivo dose response relation of inhaled fluticasone propionate (FP), adults with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Budesonide and formoterol in a single inhaler quickly gains asthma control compared with fluticasone propionate in mild asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008
Relative potency of beclomethasone propionate (BDP), delivered by HFA-MDI, and fluticasone propionate (FP) delivered by diskus Source: Eur Respir J 2003; 22: Suppl. 45, 236s Year: 2003
Synergy with salmeterol and fluticasone propionate after administration from a single inhaler (Seretide™) Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Comparison of fluticasone propionate plus theophylline with the salmeterol/fluticasone propionate combination in Japanese asthmatics Source: Eur Respir J 2005; 26: Suppl. 49, 44s Year: 2005
Salmeterol/fluticasone propionate in a single inhaler device (SLM/FP) versus theophylline (THEO)+FP in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Non-inferiority comparison of formoterol HFA (FM-HFA) pMDI with formoterol CFC (FM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 358s Year: 2007
Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001